BN-104

• UNSPSC Description:

  BN-104 (BNM-1192) is an effective selective brain membrane protein inhibitor with oral activity, and it's also a Menin inhibitor, it can block the Menin-MLL interaction and leads to the degradation of Menin protein. BN-104 is a weak hERG inhibitor, with an IC50 greater than 100 μM. BN-104 has anti-tumor activity and can be used in cancer research, such as for acute myeloid leukemia[1].

• Target Antigen:

  Epigenetic Reader Domain; Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;Membrane Transporter/Ion Channel

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bn-104.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C([C@@H]1[C@]2([H])[C@](CCC2)([H])CN1)N3CCC4(CC3)CN(C5=NC=NN=C5OC6=C(C7=CN=CN=C7C8CC8)C=C(C=C6)F)C4

• Molecular Weight:

  570.66

• References & Citations:

  [1]Taishan Hu, et al. "Discovery of a novel menin-MLL inhibitor for potential treatment of MLLr leukemias and NPM1c AML." Cancer Research. Vol. 82. No. 12. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2022.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 2

• CAS Number:

  2938995-50-5